Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 00:09 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate Resistant Prostate Cancer
NCT05037500 · Roswell Park Cancer Institute · PHASE1 · terminated · last registry update 2025-11-12 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “PI closed study” | – | Registry record, Roswell Park Cancer Institute |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CDA within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-10-08Also stopped (terminated): Taiho Oncology, Inc., Tolinapant + Decitabine + Cedazuridine (NCT05403450)
- 2026-10-06Results posted on the registry: National Cancer Institute (NCI), Cytarabine + Daunorubicin (NCT04817241)
- 2026-08-24Also stopped (suspended): National Cancer Institute (NCI), Decitabine and Cedazuridine + Venetoclax (NCT06802523)
- 2026-07-31Also stopped (suspended): National Cancer Institute (NCI), Decitabine and Cedazuridine + Paclitaxel (NCT05673200)
- 2026-05-15Also stopped (withdrawn): M.D. Anderson Cancer Center, ASTX727 + Donor Lymphocyte Infusion (NCT06297629)
- 2026-02-13Also stopped (withdrawn): M.D. Anderson Cancer Center, ASTX029 + ASTX727 (NCT06284460)
- 2026-01-09Results posted on the registry: Sanjay Mohan, Venetoclax + Decitabine (NCT05799079)
- 2026-01-09Also stopped (terminated): Sanjay Mohan, Venetoclax + Decitabine (NCT05799079)
- 2025-12-02Results posted on the registry: National Cancer Institute (NCI), KPT-8602 + Inqovi (NCT05918055)
- 2025-12-02Also stopped (terminated): National Cancer Institute (NCI), KPT-8602 + Inqovi (NCT05918055)
- 2025-10-16Also stopped (terminated): Novartis Pharmaceuticals, MBG453 + Azacitidine (NCT04878432)
- 2025-09-30Also stopped (terminated): National Cancer Institute (NCI), Deoxyribonucleic acid (DNA) methyltransferase inhibitors (DNMTi) Decitabine + Deoxyribonucleic acid (DNA) methyltransferase inhibitors (DNMTi) Cedazuridine (NCT05148234)
- 2025-09-16Results posted on the registry: National Cancer Institute (NCI), Belinostat + Decitabine and Cedazuridine (NCT04340843)
- 2025-07-31Results posted on the registry: Novartis Pharmaceuticals, MBG453 + Azacitidine (NCT04878432)
- 2025-03-24Also stopped (withdrawn): Columbia University, Thioguanine (Tabloid ®) + DecitabineCedazuridine (Inqovi ®) (NCT06351306)
- 2025-03-12Also stopped (withdrawn): M.D. Anderson Cancer Center, ASTX727 + ASTX029-01 (NCT06113289)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision